A Study Comparing Safety Of Abacavir And Lamivudine Administered Once-Daily As A Single Tablet Versus The Same Drugs Administered Twice-Daily As Separate Tablets (ALOHA Study)
NCT00094367
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
900
Enrollment
INDUSTRY
Sponsor class
Conditions
HIV Infection
Interventions
DRUG:
Abacavir/Lamivudine
Sponsor
GlaxoSmithKline